ATE429249T1 - Anti-fgf-8 antikörper gegen arthritis - Google Patents

Anti-fgf-8 antikörper gegen arthritis

Info

Publication number
ATE429249T1
ATE429249T1 AT02792021T AT02792021T ATE429249T1 AT E429249 T1 ATE429249 T1 AT E429249T1 AT 02792021 T AT02792021 T AT 02792021T AT 02792021 T AT02792021 T AT 02792021T AT E429249 T1 ATE429249 T1 AT E429249T1
Authority
AT
Austria
Prior art keywords
fgf
arthritis
antibody
antibodies against
agent
Prior art date
Application number
AT02792021T
Other languages
English (en)
Inventor
Tadafumi Tamura
Masako Uchii
Toshio Suda
Ichiro Miki
Akira Tanaka
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE429249T1 publication Critical patent/ATE429249T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02792021T 2001-12-28 2002-12-26 Anti-fgf-8 antikörper gegen arthritis ATE429249T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001400677 2001-12-28
PCT/JP2002/013650 WO2003057251A1 (fr) 2001-12-28 2002-12-26 Remedes contre l'arthrite

Publications (1)

Publication Number Publication Date
ATE429249T1 true ATE429249T1 (de) 2009-05-15

Family

ID=19189657

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02792021T ATE429249T1 (de) 2001-12-28 2002-12-26 Anti-fgf-8 antikörper gegen arthritis

Country Status (11)

Country Link
US (1) US7708999B2 (de)
EP (1) EP1466623B1 (de)
JP (1) JP4246069B2 (de)
KR (1) KR100942402B1 (de)
CN (1) CN100389826C (de)
AT (1) ATE429249T1 (de)
AU (1) AU2002361106B2 (de)
CA (1) CA2471938A1 (de)
DE (1) DE60232101D1 (de)
ES (1) ES2323949T3 (de)
WO (1) WO2003057251A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
RU2262355C1 (ru) * 2004-02-09 2005-10-20 Уракова Наталья Александровна Способ лечения артрита методом внутрисуставной инъекции суспензии лекарственных средств
ATE483799T1 (de) * 2006-06-09 2010-10-15 Hoffmann La Roche Hemmung der enzymatischen peroxidaseaktivität
PL2158315T3 (pl) 2007-06-25 2016-10-31 Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US7662858B2 (en) 2008-05-23 2010-02-16 Aaipharma, Inc. Method of treating post-surgical acute pain
CN113660944A (zh) * 2018-12-11 2021-11-16 Q32生物公司 用于补体相关疾病的融合蛋白构建体
GB2583560A (en) * 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CA3182800A1 (en) 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5491220A (en) * 1993-09-24 1996-02-13 Yeda Research And Development Co., Ltd. Surface loop structural analogues of fibroblast growth factors
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
JP3708210B2 (ja) * 1996-04-03 2005-10-19 協和醗酵工業株式会社 抗線維芽細胞増殖因子−８モノクローナル抗体
EP2264175B1 (de) * 1996-10-16 2012-11-21 ZymoGenetics, Inc. Fibroblasten-Wachstumsfaktoren-Homologe
JP4550947B2 (ja) * 1997-03-19 2010-09-22 協和発酵キリン株式会社 ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体
EP1174149A1 (de) * 1999-04-19 2002-01-23 Kyowa Hakko Kogyo Co., Ltd. Proliferationshemmstoff für androgen unabhängige tumoren
JP2001046066A (ja) * 1999-08-03 2001-02-20 Kyowa Hakko Kogyo Co Ltd 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体
DE60226253T2 (de) * 2001-06-28 2009-05-14 Kyowa Hakko Kogyo Co., Ltd. Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers

Also Published As

Publication number Publication date
CN1607961A (zh) 2005-04-20
WO2003057251A1 (fr) 2003-07-17
JPWO2003057251A1 (ja) 2005-05-12
KR100942402B1 (ko) 2010-02-17
AU2002361106B2 (en) 2007-06-07
ES2323949T3 (es) 2009-07-28
AU2002361106A1 (en) 2003-07-24
CA2471938A1 (en) 2003-07-17
CN100389826C (zh) 2008-05-28
DE60232101D1 (de) 2009-06-04
US7708999B2 (en) 2010-05-04
EP1466623A4 (de) 2006-05-17
KR20040078652A (ko) 2004-09-10
EP1466623B1 (de) 2009-04-22
EP1466623A1 (de) 2004-10-13
US20050175608A1 (en) 2005-08-11
JP4246069B2 (ja) 2009-04-02

Similar Documents

Publication Publication Date Title
DE69728585D1 (de) Mittel gegen Juckreiz
ATE341142T1 (de) System und verfahren zur ausführung einer gegen crawler angriff geschützten web-seite
EA200100411A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
ID25764A (id) Turunan-turunan ftalamida, atau garam-garamnya untuk insektisida agroholtikultura, dan metode penggunaannya
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
BR9909242A (pt) Inibidores de fosfolipase a2
ID27833A (id) METODA UNTUK MENGOBATI ATEROSKLEROSIS DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
DE602004017325D1 (de) (2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl)-l-phenylalanylü-2-pyrrolidincarbonitril-p-toluolsulfonsäuresalz und wasserfreie kristalline formen davon
MXPA02011427A (es) Procedimiento para revestir dispositivos medicos utilizando dioxido de carbono supercritico.
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
ATE420947T1 (de) Gewebeimplant zur wiederherstellung von knorpelgewebe
BR0106838B1 (pt) método de sintetizar uma mistura de polìmeros, e, mistura de polìmeros.
DK1414956T3 (da) Höjt påvirkningsresistente granula
ITTO20010102A0 (it) Sistema e metodo di saldatura laser remota.
WO2003039470A3 (en) Polyvalent immunogen of hiv
ITMO20030057A0 (it) Dispositivo per la confezione,la miscelazione e l'applicazione di cemento osseo.
PT1353689E (pt) Composicoes imunizantes e metodos de utilizacao
ATE429249T1 (de) Anti-fgf-8 antikörper gegen arthritis
SV2002000227A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida caso 20502
EA200400280A1 (ru) Новые неочищенные и кристаллические формы гидрохлорида лерканидипина
PT1413305E (pt) Derivados aril (ou heteroaril) azolilcabrinol para o tratamento de incontinencia urinaria
DE60129032D1 (de) Creatinester-pronutrient-verbindungen und formulierungen
ITMC20020011A1 (it) Metodo e relativo impianto per l'incisione laser di lastre o cilindricalcografici.
ITRM20020533A0 (it) Procedimento ed apparecchio di trattamento di liquidi di scarico.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties